Log In
Print this Print this

ozoralizumab (formerly Anti-TNF nanobody, ATN-103, PF-5230896)

  Manage Alerts
Collapse Summary General Information
Company Ablynx N.V.
DescriptionNanobody against tumor necrosis factor (TNF) alpha
Molecular Target Tumor necrosis factor (TNF) alpha
Mechanism of ActionTumor necrosis factor (TNF) alpha inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerEddingpharm Inc.;
Taisho Pharmaceutical Holdings Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today